article thumbnail

Advancements in hit identification for membrane protein drug discovery

Drug Target Review

The challenge of GPCR drug discovery G protein-coupled receptors (GPCRs) are one of the most desirable and challenging target classes in drug discovery, as their mutation can lead to a wide range of diseases such as cancer, cardiovascular disorders and neurological conditions.

article thumbnail

High Throughput Screening (HTS)

Sygnature Discovery

Employing a comprehensive strategy for hit identification, we use the most effective methods to accurately pinpoint hit series that have the highest potential for evolving into compounds with drug-like properties. These include quality robust assays, reliable automation, secure data, and the quality of the libraries.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Advancing Precision Oncology: Leveraging multidimensional biomarker insights with CGIP for efficient drug development and enhanced patient outcomes

Fierce BioTech

Advancing Precision Oncology: Leveraging multidimensional biomarker insights with CGIP for efficient drug development and enhanced patient outcomes scox Wed, 04/16/2025 - 17:44 Thu, 05/29/2025 - 11:00 Resource Type Webinar Taylor Jensen, Ph.D. Precision oncology drug development faces increasing costs and complexity.

article thumbnail

RNA processing in health and disease: challenges and opportunities of the field

Drug Target Review

In this article Drug Target Review’s Izzy Wood spoke to Sam Hasson, Director of Target Biology at Rgenta Therapeutics, a biotech firm in Massachusetts, US, that aims to develop small molecule therapeutics to target RNA processing. Ribonucleic acid strands consisting of nucleotides important for protein bio-synthesis entering cell.

RNA 96
article thumbnail

9th RSC-BMCS Fragment-based Drug Discovery Meeting

Zobio

In person ZoBio attended the 9th RSC-BMCS Fragment-based Drug Discovery meeting in Cambridge. The meeting focused on case studies in Fragment-based Drug Discovery that have delivered compounds to late stage medicinal chemistry, preclinical or clinical programs.

article thumbnail

9th RSC-BMCS Fragment-based Drug Discovery Meeting

Zobio

In person ZoBio attended the 9th RSC-BMCS Fragment-based Drug Discovery meeting in Cambridge. The meeting focused on case studies in Fragment-based Drug Discovery that have delivered compounds to late stage medicinal chemistry, preclinical or clinical programs.

article thumbnail

Integrating Bioanalytical Automation, Biomarkers, Pharmacogenomics, & Cost-Effective Strategies

Conversations in Drug Development Trends

Tom Zhang, PhD, Chief Scientific Officer, Large Molecule Bioanalysis Revolutionizing Therapeutic Development with Cutting-Edge Bioanalysis Automation Cutting-edge advancements in bioanalysis (BioA) and drug R&D are reshaping the future of preventative and interventional care, but how do we harness these to their fullest potential?